Johnson & Johnson’s (JNJ) third-quarter 2024 earnings came in at $2.42 per share, which beat the Zacks Consensus Estimate of $2.22. Earnings declined 9% from the year-ago period.Adjusted earnings exclude a one-time special charge, including which, reported earnings were $1.11 per share, down 34.3% year over year.Sales of this drug and medical devices giant came in at $22.47 billion, which beat the Zacks Consensus Estimate of $22.19 billion. Sales rose 5.2% from the year-ago quarter, reflecting an operationa ...

Shares of Johnson & Johnson (NYSE:JNJ) are up 2.4% to trade at $165.43 this morning, after the company posted a third-quarter beat and hiked its full-year revenue guidance. The Cincinnati-based equity also shared a quarterly cash dividend of $1.24 per share, payable on Dec. 10.On the charts, JNJ is breaking above recent pressure at the 20-day moving average. This morning's earlier pullback was caught by firm support at the $59 level. Year to date, the equity is up 5.6%. Analyst sentiment has been lukewarm, ...

Key Takeaways Johnson & Johnson's third-quarter profit fell sharply due to billions in one-time expenses like legal costs. The company's adjusted profit beat estimates, as did revenue. The pharmaceutical and medical device company also lifted its full-year sales outlook, but lowered profit projections to account for a recently completed acquisition. Johnson & Johnson (JNJ) posted better sales than expected for the third quarter, but profit fell short of analysts' estimates as the company reported billions i ...

For the quarter ended September 2024, Johnson & Johnson (JNJ) reported revenue of $22.47 billion, up 5.3% over the same period last year. EPS came in at $2.42, compared to $2.66 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $22.19 billion, representing a surprise of +1.27%. The company delivered an EPS surprise of +9.01%, with the consensus EPS estimate being $2.22.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of JNJ either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any in ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.01%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.71 per share when it actually produced earnings of $2.82, delivering a surprise of 4.06%.Over ...

3rd Quarter 2024 Results' 3rd Quarter 2024 Sales Worldwide increased Excluding acquisitions / divestitures on an operational basis Worldwide increased ▲ Diluted earnings per share3 Decreased ▼ Adjusted diluted earnings per share* Joaquin Duato Chairman & Chief Executive Officer Johnson & Johnson 66 Johnson & Johnson's strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation. During the quarter, we advanced our pipeline ...

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied SAVANNAH, Ga., Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized myasthenia gravis (gMG). Study participants who were treated with nipocalimab plu ...

Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------|---------|--------|-------------------------|-------------------------------|----------| | (Unaudited; Dollars in Millions) \nSales to customers by geographic area | 2024 | 2023 | THIRD QUARTER \nTotal | Percent Change \nOperations | Currency | | U.S. | $12,909 | 11,996 | 7.6 % | 7.6 | — | | Europe | 4,914 ...

Johnson & Johnson JNJ will release earnings results for its third quarter before the opening bell on Tuesday, Oct. 15.Analysts expect the New Brunswick, New Jersey-based bank to report quarterly earnings at $2.21 per share, down from $2.66 per share in the year-ago period. Johnson & Johnson projects to report revenue of $22.16 billion for the recent quarter, compared to $21.03 billion a year earlier, according to data from Benzinga Pro.On Oct. 9, Johnson & Johnson said it has completed acquisition of V-Wave ...